OverviewSuggest Edit

Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

TypePublic
Founded1979
HQPlymouth Meeting, US
Websiteinovio.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Feb 2019)281(+2%)
Job Openings11
Revenue (FY, 2018)$30.5 M(-27%)
Share Price (Oct 2019)$2.5 (+13%)

Key People/Management at Inovio Pharmaceuticals

J. Joseph Kim

J. Joseph Kim

CEO
Peter Kies

Peter Kies

CFO
Niranjan Sardesai

Niranjan Sardesai

COO
Mark Bagarazzi

Mark Bagarazzi

Chief Medical Officer
Show more

Inovio Pharmaceuticals Office Locations

Inovio Pharmaceuticals has offices in Plymouth Meeting and San Diego
Plymouth Meeting, US (HQ)
660 W Germantown Pike #110
San Diego, US
10480 Wateridge Cir
San Diego, US
6769 Mesa Ridge Rd
Show all (3)

Inovio Pharmaceuticals Financials and Metrics

Inovio Pharmaceuticals Revenue

Inovio Pharmaceuticals's revenue was reported to be $30.48 m in FY, 2018
USD

Revenue (Q2, 2019)

135.7k

Net income (Q2, 2019)

(29.6m)

EBIT (Q2, 2019)

(28.2m)

Market capitalization (16-Oct-2019)

248.6m

Closing stock price (16-Oct-2019)

2.5

Cash (30-Jun-2019)

19.7m
Inovio Pharmaceuticals's current market capitalization is $248.6 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

13.5m10.5m40.6m35.4m42.2m30.5m

Revenue growth, %

(22%)288%(79%)

General and administrative expense

13.6m18.1m23.9m28.3m29.3m

R&D expense

21.4m57.8m88.7m98.6m95.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

9.5m2.4m3.8m1.8m5.2m5.3m24.2m8.1m6.2m12.5m10.4m20.4m2.6m1.5m24.4m2.0m2.8m135.7k

General and administrative expense

3.3m4.1m4.3m3.2m4.1m4.7m4.4m5.4m5.8m5.8m7.8m6.2m6.3m9.7m7.2m6.8m7.0m5.9m

R&D expense

5.4m8.2m9.6m7.0m9.4m16.7m16.1m18.2m19.6m27.0m24.5m23.9m25.5m24.6m22.5m21.9m24.4m22.5m

Operating expense total

8.7m12.4m14.0m10.2m13.5m20.4m20.5m23.6m24.4m32.7m32.3m30.0m31.8m34.3m29.7m28.6m31.4m28.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

33.7m40.5m57.6m19.1m23.8m23.7m

Accounts Receivable

3.3m2.8m7.3m15.8m6.0m3.3m

Inventories

637.4k798.0k917.3k1.7m

Current Assets

58.7m98.9m171.9m124.6m138.4m87.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

33.1m98.8m88.5m70.7m26.1m70.3m85.5m41.6m28.5m23.3m22.9m23.9m23.3m37.5m15.1m19.4m20.8m19.7m

Accounts Receivable

10.6m2.7m2.9m1.6m3.3m5.6m11.0m11.2m10.4m17.5m9.9m7.5m6.2m5.1m1.7m2.8m2.8m130.2k

Current Assets

57.9m121.7m112.9m104.6m87.3m162.1m184.1m160.6m148.0m140.2m106.8m106.9m154.6m123.8m101.8m93.6m134.9m110.5m

PP&E

2.3m4.5m4.6m5.5m6.5m8.4m8.7m9.0m9.8m15.0m18.5m17.5m16.9m16.2m15.2m14.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(66.1m)(36.1m)(29.1m)(73.7m)(88.2m)(97.0m)

Depreciation and Amortization

2.1m1.6m1.9m3.1m3.5m5.0m

Inventories

(229.7k)(160.5k)(119.3k)(831.8k)

Accounts Payable

2.2m1.5m6.5m6.4m2.8m550.4k
Quarterly
USDY, 2019

Financial Leverage

2.9 x
Show all financial metrics

Inovio Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

620
Show all operating metrics

Inovio Pharmaceuticals Online and Social Media Presence

Embed Graph

Inovio Pharmaceuticals News and Updates

Lyme Disease H2 2019 Pipeline Review, with Focus on Key Players such as Inovio Pharmaceuticals and Valneva SE

DUBLIN, Oct. 9, 2019 /PRNewswire/ -- The "Lyme Disease - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. The Lyme Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Lyme Disease...

Inovio Pharmaceuticals to Present at H.C. Wainwright Global Life Sciences Conference in London, UK

PLYMOUTH MEETING, Pa., March 27, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019 at 4:10 p.m. local time. The conference is being held at the...

Inovio Pharmaceuticals stock up 9% after company announces positive data from Phase 1 trial of Ebola vaccine

Shares of Inovio Pharmaceuticals Inc. rose 9% in premarket trade Thursday after the company announced that its investigational Ebola vaccine was able to elicit a strong antibody response in the majority of subjects in a Phase 1 trial. The vaccine, dubbed INO-4201, was given to 70 subjects either th…

Inovio Pharmaceuticals Reports 2018 Fourth Quarter and Year-End Financial Results

PLYMOUTH MEETING, Pa., March 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA immunotherapies targeted against cancers and infectious diseases, today reported financial results...

Inovio Pharmaceuticals Completes Sale of Additional Convertible Senior Notes

PLYMOUTH MEETING, Pa., March 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the sale of additional 6.50% convertible senior notes due 2024 (the "notes"), bringing the total amount of notes sold to $78.5 million in aggregate principal amount. The...

Inovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

PLYMOUTH MEETING, Pa., Feb. 13, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today its intention to offer, subject to market and other conditions, $65 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering...
Show more

Inovio Pharmaceuticals Frequently Asked Questions

  • When was Inovio Pharmaceuticals founded?

    Inovio Pharmaceuticals was founded in 1979.

  • Who are Inovio Pharmaceuticals key executives?

    Inovio Pharmaceuticals's key executives are J. Joseph Kim, Peter Kies and Niranjan Sardesai.

  • How many employees does Inovio Pharmaceuticals have?

    Inovio Pharmaceuticals has 281 employees.

  • What is Inovio Pharmaceuticals revenue?

    Latest Inovio Pharmaceuticals annual revenue is $30.5 m.

  • What is Inovio Pharmaceuticals revenue per employee?

    Latest Inovio Pharmaceuticals revenue per employee is $108.5 k.

  • Who are Inovio Pharmaceuticals competitors?

    Competitors of Inovio Pharmaceuticals include Athersys, Reata Pharmaceuticals and PTC Therapeutics.

  • Where is Inovio Pharmaceuticals headquarters?

    Inovio Pharmaceuticals headquarters is located at 660 W Germantown Pike #110, Plymouth Meeting.

  • Where are Inovio Pharmaceuticals offices?

    Inovio Pharmaceuticals has offices in Plymouth Meeting and San Diego.

  • How many offices does Inovio Pharmaceuticals have?

    Inovio Pharmaceuticals has 3 offices.